Compare Viatris Inc (VTRS) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Viatris Inc trades at $17.4 (market cap $20.12B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.55 (market cap $339.46M). The key difference: Viatris Inc is far larger — about 59.3× Roundhill S&P 500 0DTE Covered Call Strategy ETF's market cap, and Viatris Inc pays a 2.74% dividend while Roundhill S&P 500 0DTE Covered Call Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 54 Days on average.
| VTRS | XDTE | |
|---|---|---|
Market Cap | $20.12B | $339.46M |
Volume | 7,543,511 | 214,614 |
Sector | Health | Income / Options Overlay |
52-Week High | $18.27 | $44.76 |
52-Week Low | $9.74 | $36.00 |
Typical Hold Time | 57 Days | 54 Days |
Enterprise Value | $32.24B | — |
Dividend Yield | 2.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue trends show a slight decline from $16.3B in 2022 to $14.3B in 2025, but net losses have widened significantly, reaching -$3.51B in 2025. Positive cash flow generation and a dividend payment scheduled for September 2026 highlight financial stability amid profitability challenges.
The outlook for VTRS is mixed; analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside, supported by strong cash flow and recent product approvals. However, persistent net losses, high P/E ratio of 236.2, and substantial long-term debt of $14.04B pose risks. Investors should weigh the potential for operational turnaround against ongoing profitability concerns and competitive pressures in the healthcare sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
